EP Patent

EP3838271B1 — Treating elevated levels of eosinophils and/or basophils

Assigned to Areteia Therapeutics Inc · Expires 2025-09-03 · 1y expired

What this patent protects

Patent listed against pramipexole-dihydrochloride.

Drugs covered by this patent

pramipexole-dihydrochloride (PRAMIPEXOLE DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP3838271B1
Jurisdiction: EP
Classification: —
Expires: 2025-09-03
Drug substance claim: No
Drug product claim: No
Assignee: Areteia Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.